CVR number 35635262
Industry 46.4620 Wholesale of pharmaceutical goods

HOSPITECH DANMARK ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  4.3% 2.5% 3.9% 5.2% 3.9%  
Credit score (0-100)  49 62 49 42 49  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  1,098 1,375 1,802 2,142 2,194  
EBITDA  507 602 761 1,148 1,031  
EBIT  251 359 610 1,148 1,009  
Pre-tax profit (PTP)  234.0 345.3 594.4 1,135.9 1,023.1  
Net earnings  75.4 269.2 423.0 885.4 797.0  
Pre-tax profit without non-rec. items  234 345 594 1,136 1,023  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  394 151 0.0 0.0 139  
Shareholders equity total  875 1,034 1,457 935 847  
Interest-bearing liabilities  303 272 241 260 734  
Balance sheet total (assets)  1,416 1,702 2,234 1,940 2,551  
Net Debt  116 -227 -703 -763 -721  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,098 1,375 1,802 2,142 2,194  
Gross profit growth  -67.1% 25.3% 31.1% 18.8% 2.4%  
Employees  0 2 2 2 3  
Employee growth %  0.0% 0.0% 0.0% 0.0% 50.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,416 1,702 2,234 1,940 2,551  
Balance sheet change%  -12.4% 20.2% 31.3% -13.1% 31.5%  
Added value  506.9 601.7 760.9 1,298.3 1,030.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -499 -486 -301 0 117  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  22.8% 26.1% 33.9% 53.6% 46.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  16.5% 23.0% 31.0% 55.0% 46.0%  
ROI %  21.6% 32.4% 40.6% 79.3% 74.4%  
ROE %  8.5% 28.2% 34.0% 74.0% 89.4%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  44.6% 60.8% 65.2% 48.2% 33.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  22.9% -37.7% -92.4% -66.5% -70.0%  
Gearing %  34.6% 26.3% 16.5% 27.8% 86.7%  
Net interest  0 0 0 0 0  
Financing costs %  4.1% 4.6% 6.2% 4.7% 1.9%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  1.9 3.8 2.9 1.9 1.3  
Current Ratio  1.9 3.8 2.9 1.9 1.4  
Cash and cash equivalent  186.7 499.3 944.2 1,022.3 1,455.1  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  481.5 1,123.3 1,456.8 935.4 708.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 301 380 649 344  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 301 380 574 344  
EBIT / employee  0 179 305 574 336  
Net earnings / employee  0 135 211 443 266